Zymeworks (ZYME) Income from Continuing Operations (2021 - 2026)
Zymeworks (ZYME) posted Income from Continuing Operations of 44162000.0 for Q1 2026, down 7.17% sequentially from 41209000.0 in Q4 2025, and down 95.1% YoY from 900586515.32 in Q1 2025.
Powered by 
Analysis
Zymeworks (ZYME) Income from Continuing Operations (2021 - 2026) Analysis & Trends
Zymeworks has reported Income from Continuing Operations for 6 years, with the latest figure at 44162000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 95.1% year-over-year to 44162000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 102656000.0 (up 9.7% YoY) and the FY2025 annual result came in at 81130000.0, up 33.88% from the prior year.
- Income from Continuing Operations declined to 44162000.0 in Q1 2026 per ZYME's latest filing, from 41209000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 309431000.0 in Q4 2022 and troughed at 72625000.0 in Q1 2022.
- A 5-year average of 14254117.65 and a median of 29850000.0 in 2024 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2023: Income from Continuing Operations jumped 890.33% in 2022, then plunged 104.68% in 2023.
- Over 5 years, Income from Continuing Operations stood at 309431000.0 in 2022, then slumped by 104.68% to 14482000.0 in 2023, then tumbled by 62.31% to 23506000.0 in 2024, then slumped by 75.31% to 41209000.0 in 2025, then decreased by 7.17% to 44162000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 44162000.0, 41209000.0, and 19602000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Zymeworks | 2.15 Bn | 1.88 Bn | - | -45.02 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -45.02 Mn |
| Mar 31, 2026 | -44.16 Mn |
| Dec 31, 2025 | -41.21 Mn |
| Sep 30, 2025 | -19.60 Mn |
| Jun 30, 2025 | 2.32 Mn |
| Mar 31, 2025 | -22.64 Mn |
| Dec 31, 2024 | -23.51 Mn |
| Sep 30, 2024 | -29.85 Mn |
| Jun 30, 2024 | -37.69 Mn |
| Mar 31, 2024 | -31.65 Mn |
| Dec 31, 2023 | -14.48 Mn |
| Sep 30, 2023 | -28.69 Mn |
| Jun 30, 2023 | -51.15 Mn |
| Mar 31, 2023 | -24.35 Mn |
| Dec 31, 2022 | 309.43 Mn |
| Sep 30, 2022 | -47.85 Mn |
| Jun 30, 2022 | -64.62 Mn |
| Mar 31, 2022 | -72.63 Mn |
| Dec 31, 2021 | -39.15 Mn |
| Sep 30, 2021 | -60.58 Mn |